The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review
Open Access
- 22 March 2022
- journal article
- review article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 3 (5) , 100315
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb Co
This publication has 39 references indexed in Scilit:
- Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 2017
- Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesotheliomaOncoImmunology, 2017
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trialThe Lancet Oncology, 2017
- The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in MesotheliomaJournal of Thoracic Oncology, 2017
- Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)Lung Cancer, 2016
- Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomasHuman Pathology, 2016
- Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviewsSystematic Reviews, 2016
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)PLOS ONE, 2015
- B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor PrognosisJournal of Thoracic Oncology, 2014